Download PDF
Semin Neurol 2023; 43(01): 004-016
DOI: 10.1055/s-0043-1764140
Review Article

Global Epidemiology of Movement Disorders: Rare or Underdiagnosed?

Sarah A. O'Shea
1   Department of Neurology, Columbia University, Vagelos College of Physicians and Surgeons, New York City, New York
,
Ludy C. Shih
2   Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
3   Department of Neurology, Boston Medical Center, Boston, Massachusetts
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

In this manuscript, we review the epidemiology of movement disorders including Parkinson's disease (PD), atypical parkinsonism, essential tremor, dystonia, functional movement disorders, tic disorders, chorea, and ataxias. We emphasize age-, sex-, and geography-based incidence and prevalence, as well as notable trends including the rising incidence and prevalence of PD. Given the growing global interest in refining clinical diagnostic skills in recognizing movement disorders, we highlight some key epidemiological findings that may be of interest to clinicians and health systems tasked with diagnosing and managing the health of patients with movement disorders.

Keywords

epidemiology - parkinsonism - dystonia - essential tremor - atypical parkinsonism - tic disorders - ataxia - chorea - Huntington's disease


Publication History

Article published online:
09 March 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Fahn S. Classification of movement disorders. Mov Disord 2011; 26 (06) 947-957
    CrossrefPubMedGoogle Scholar
  • 2 Bach JP, Ziegler U, Deuschl G, Dodel R, Doblhammer-Reiter G. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov Disord 2011; 26 (12) 2286-2290
    CrossrefPubMedGoogle Scholar
  • 3 Fereshtehnejad SM, Rahmani A, Shafieesabet M. et al. Prevalence and associated comorbidities of restless legs syndrome (RLS): data from a large population-based door-to-door survey on 19176 adults in Tehran, Iran. PLoS One 2017; 12 (02) e0172593
    CrossrefPubMedGoogle Scholar
  • 4 Fereshtehnejad SM, Shafieesabet M, Rahmani A. et al. A novel 6-item screening questionnaire for Parkinsonism: validation and comparison between different instruments. Neuroepidemiology 2014; 43 (3-4): 178-193
    CrossrefPubMedGoogle Scholar
  • 5 Wei Z, Xiaoyuan N, Shengwei G, Zhizong H, Jiyuan L, Yang L. Evaluation of a screening questionnaire for Parkinson's disease in a Chinese population. J Clin Neurosci 2014; 21 (02) 278-281
    CrossrefPubMedGoogle Scholar
  • 6 Sernadela P, González-Castro L, Carta C. et al. Linked registries: connecting rare diseases patient registries through a semantic web layer. BioMed Res Int 2017; 2017: 8327980
    CrossrefPubMedGoogle Scholar
  • 7 Sugawara M, Watanabe S, Toyoshima I. Prevalence of dystonia in Akita Prefecture in Northern Japan. Mov Disord 2006; 21 (07) 1047-1049
    CrossrefPubMedGoogle Scholar
  • 8 Sugawara N, Yasui-Furukori N, Umeda T. et al. Clock drawing performance in a community-dwelling population: Normative data for Japanese subjects. Aging Ment Health 2010; 14 (05) 587-592
    CrossrefPubMedGoogle Scholar
  • 9 Lolekha P, Phanthumchinda K, Bhidayasiri R. Prevalence and risk factors of Parkinson's disease in retired Thai traditional boxers. Mov Disord 2010; 25 (12) 1895-1901
    CrossrefPubMedGoogle Scholar
  • 10 Lolekha P, Tangkanakul C, Saengchatri T, Kulkeartprasert P. The Six-item Clock-Drawing Scoring System: a rapid screening for cognitive impairment in Parkinson's disease. Psychogeriatrics 2021; 21 (01) 24-31
    CrossrefPubMedGoogle Scholar
  • 11 Jagota P, Srivanitchapoom P, Petchrutchatachart S. et al. Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. J Mov Disord 2022; 15 (02) 151-155
    CrossrefPubMedGoogle Scholar
  • 12 World Health O.. Parkinson Disease: A Public Health Approach: Technical Brief. World Health Organization; 2022. Accessed February 10, 2023 at: https://apps.who.int/iris/handle/10665/355973
    PubMedGoogle Scholar
  • 13 GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17 (11) 939-953
    CrossrefPubMedGoogle Scholar
  • 14 Dorsey ER, Bloem BR. The Parkinson pandemic-a call to action. JAMA Neurol 2018; 75 (01) 9-10
    CrossrefPubMedGoogle Scholar
  • 15 Twelves D, Perkins KSM, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003; 18 (01) 19-31
    CrossrefPubMedGoogle Scholar
  • 16 Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology 2016; 46 (04) 292-300
    CrossrefPubMedGoogle Scholar
  • 17 Willis AW, Roberts E, Beck JC. et al; Parkinson's Foundation P4 Group. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis 2022; 8 (01) 170
    CrossrefPubMedGoogle Scholar
  • 18 Allen L. Are we facing a noncommunicable disease pandemic?. J Epidemiol Glob Health 2017; 7 (01) 5-9
    CrossrefPubMedGoogle Scholar
  • 19 Zhong QQ, Zhu F. Trends in prevalence cases and disability-adjusted life-years of Parkinson's disease: findings from the Global Burden of Disease Study 2019. Neuroepidemiology 2022; 56 (04) 261-270
    CrossrefPubMedGoogle Scholar
  • 20 Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X. Projection of the prevalence of Parkinson's disease in the coming decades: revisited. Mov Disord 2018; 33 (01) 156-159
    CrossrefPubMedGoogle Scholar
  • 21 Marras C, Beck JC, Bower JH. et al; Parkinson's Foundation P4 Group. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis 2018; 4: 21
    CrossrefPubMedGoogle Scholar
  • 22 Kissani N, Liqali L, Hakimi K. et al. Why does Africa have the lowest number of neurologists and how to cover the gap?. J Neurol Sci 2022; 434: 120119
    CrossrefPubMedGoogle Scholar
  • 23 Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol 2020; 19 (02) 170-178
    CrossrefPubMedGoogle Scholar
  • 24 Nalls MA, Blauwendraat C, Vallerga CL. et al; 23andMe Research Team, System Genomics of Parkinson's Disease Consortium, International Parkinson's Disease Genomics Consortium. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019; 18 (12) 1091-1102
    CrossrefPubMedGoogle Scholar
  • 25 Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18 (R1): R48-R59
    CrossrefPubMedGoogle Scholar
  • 26 Kim CY, Alcalay RN. Genetic forms of Parkinson's disease. Semin Neurol 2017; 37 (02) 135-146
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Cook L, Schulze J, Verbrugge J. et al; ClinGen Parkinson's Disease Gene Curation Expert Panel and the MDS Task Force for Recommendations for Genetic Testing in Parkinson's Disease, Clinical Genome Resource (ClinGen) Parkinson's Disease Gene Curation Expert Panel Authors, Movement Society Disorder (MDS) Task Force on Recommendations for Clinical Genetic Testing in Parkinson's Disease Authors. The commercial genetic testing landscape for Parkinson's disease. Parkinsonism Relat Disord 2021; 92: 107-111
    CrossrefPubMedGoogle Scholar
  • 28 Alcalay RN, Mirelman A, Saunders-Pullman R. et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 2013; 28 (14) 1966-1971
    CrossrefPubMedGoogle Scholar
  • 29 Healy DG, Falchi M, O'Sullivan SS. et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7 (07) 583-590
    CrossrefPubMedGoogle Scholar
  • 30 Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord 2013; 28 (06) 697-701
    CrossrefPubMedGoogle Scholar
  • 31 Ando M, Funayama M, Li Y. et al. VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov Disord 2012; 27 (11) 1413-1417
    CrossrefPubMedGoogle Scholar
  • 32 Zimprich A, Benet-Pagès A, Struhal W. et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89 (01) 168-175
    CrossrefPubMedGoogle Scholar
  • 33 Bonifati V, Rohé CF, Breedveld GJ. et al; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65 (01) 87-95
    CrossrefPubMedGoogle Scholar
  • 34 Ibáñez P, Lesage S, Lohmann E. et al; French Parkinson's Disease Genetics Study Group. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006; 129 (Pt 3): 686-694
    CrossrefPubMedGoogle Scholar
  • 35 Kilarski LL, Pearson JP, Newsway V. et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord 2012; 27 (12) 1522-1529
    CrossrefPubMedGoogle Scholar
  • 36 Rogaeva E, Johnson J, Lang AE. et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004; 61 (12) 1898-1904
    CrossrefPubMedGoogle Scholar
  • 37 Valente EM, Salvi S, Ialongo T. et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56 (03) 336-341
    CrossrefPubMedGoogle Scholar
  • 38 Klein C, Djarmati A, Hedrich K. et al. PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism. Eur J Hum Genet 2005; 13 (09) 1086-1093
    CrossrefPubMedGoogle Scholar
  • 39 Bonifati V, Rizzu P, van Baren MJ. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299 (5604): 256-259
    CrossrefPubMedGoogle Scholar
  • 40 Riboldi GM, Di Fonzo AB. GBA, Gaucher disease, and Parkinson's disease: from genetic to clinic to new therapeutic approaches. Cells 2019; 8 (04) 364
    CrossrefPubMedGoogle Scholar
  • 41 Anheim M, Elbaz A, Lesage S. et al; French Parkinson Disease Genetic Group. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78 (06) 417-420
    CrossrefPubMedGoogle Scholar
  • 42 Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of glucocerebrosidase (GBA) mutations in Parkinson's disease: a kin cohort study. Mov Disord 2020; 35 (11) 2111-2114
    CrossrefPubMedGoogle Scholar
  • 43 Gao HM, Hong JS. Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol 2011; 94 (01) 1-19
    CrossrefPubMedGoogle Scholar
  • 44 Ball N, Teo WP, Chandra S, Chapman J. Parkinson's disease and the environment. Front Neurol 2019; 10: 218
    CrossrefPubMedGoogle Scholar
  • 45 Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52 (03) 276-284
    CrossrefPubMedGoogle Scholar
  • 46 Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth Jr WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155 (08) 732-738
    CrossrefPubMedGoogle Scholar
  • 47 Chen H, Huang X, Guo X. et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74 (11) 878-884
    CrossrefPubMedGoogle Scholar
  • 48 World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Smoking 2000–2025. Published online 2018. Accessed February 10, 2023 at: https://www.who.int/publications/i/item/9789240039322
    PubMed
  • 49 Ullah I, Zhao L, Hai Y. et al. “Metal elements and pesticides as risk factors for Parkinson's disease - a review”. Toxicol Rep 2021; 8: 607-616
    CrossrefPubMedGoogle Scholar
  • 50 Vlaar T, Kab S, Schwaab Y, Fréry N, Elbaz A, Moisan F. Association of Parkinson's disease with industry sectors: a French nationwide incidence study. Eur J Epidemiol 2018; 33 (11) 1101-1111
    CrossrefPubMedGoogle Scholar
  • 51 Cicero CE, Mostile G, Vasta R. et al. Metals and neurodegenerative diseases. A systematic review. Environ Res 2017; 159: 82-94
    CrossrefPubMedGoogle Scholar
  • 52 Lee PC, Raaschou-Nielsen O, Lill CM. et al. Gene-environment interactions linking air pollution and inflammation in Parkinson's disease. Environ Res 2016; 151: 713-720
    CrossrefPubMedGoogle Scholar
  • 53 Ritz BR, Paul KC, Bronstein JM. Of pesticides and men: a California story of genes and environment in Parkinson's disease. Curr Environ Health Rep 2016; 3 (01) 40-52
    CrossrefPubMedGoogle Scholar
  • 54 Jo S, Kim YJ, Park KW. et al. Association of NO2 and other air pollution exposures with the risk of Parkinson disease. JAMA Neurol 2021; 78 (07) 800-808
    CrossrefPubMedGoogle Scholar
  • 55 Gorell JM, Johnson CC, Rybicki BA. et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999; 20 (2-3): 239-247
    PubMedGoogle Scholar
  • 56 Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 2011; 26 (07) 547-555
    CrossrefPubMedGoogle Scholar
  • 57 Kamel F, Tanner C, Umbach D. et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 2007; 165 (04) 364-374
    CrossrefPubMedGoogle Scholar
  • 58 Baltazar MT, Dinis-Oliveira RJ, de Lourdes Bastos M, Tsatsakis AM, Duarte JA, Carvalho F. Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases–a mechanistic approach. Toxicol Lett 2014; 230 (02) 85-103
    CrossrefPubMedGoogle Scholar
  • 59 Singh N, Lawana V, Luo J. et al. Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events. Neurobiol Dis 2018; 117: 82-113
    CrossrefPubMedGoogle Scholar
  • 60 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Eleventh Biennial Update). Veterans and Agent Orange: Update 11 (2018). Washington (DC): National Academies Press (US); ; November 15, 2018
    Google Scholar
  • 61 Stellman JM, Stellman SD. Agent Orange during the Vietnam War: the lingering issue of its civilian and military health impact. Am J Public Health 2018; 108 (06) 726-728
    CrossrefPubMedGoogle Scholar
  • 62 Paul KC, Sinsheimer JS, Cockburn M, Bronstein JM, Bordelon Y, Ritz B. Organophosphate pesticides and PON1 L55M in Parkinson's disease progression. Environ Int 2017; 107: 75-81
    CrossrefPubMedGoogle Scholar
  • 63 Viscidi E, Litvan I, Dam T. et al. Clinical features of patients with progressive supranuclear palsy in an US insurance claims database. Front Neurol 2021; 12: 571800
    CrossrefPubMedGoogle Scholar
  • 64 Respondek G, Stamelou M, Kurz C. et al; Movement Disorder Society-endorsed PSP Study Group. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29 (14) 1758-1766
    CrossrefPubMedGoogle Scholar
  • 65 Swallow DMA, Zheng CS, Counsell CE. Systematic review of prevalence studies of progressive supranuclear palsy and corticobasal syndrome. Mov Disord Clin Pract (Hoboken) 2022; 9 (05) 604-613
    CrossrefPubMedGoogle Scholar
  • 66 Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354 (9192): 1771-1775
    CrossrefPubMedGoogle Scholar
  • 67 Bjornsdottir A, Gudmundsson G, Blondal H, Olafsson E. Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry 2013; 84 (02) 136-140
    CrossrefPubMedGoogle Scholar
  • 68 Adler CH, Beach TG, Zhang N. et al. Clinical diagnostic accuracy of early/advanced parkinson disease: an updated clinicopathologic study. Neurol Clin Pract 2021; 11 (04) e414-e421
    CrossrefPubMedGoogle Scholar
  • 69 Koga S, Dickson DW. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J Neurol Neurosurg Psychiatry 2018; 89 (02) 175-184
    CrossrefPubMedGoogle Scholar
  • 70 Koga S, Aoki N, Uitti RJ. et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology 2015; 85 (05) 404-412
    CrossrefPubMedGoogle Scholar
  • 71 Martin WRW, Miles M, Zhong Q. et al. Is levodopa response a valid indicator of Parkinson's disease?. Mov Disord 2021; 36 (04) 948-954
    CrossrefPubMedGoogle Scholar
  • 72 Bhatia KP, Bain P, Bajaj N. et al; Tremor Task Force of the International Parkinson and Movement Disorder Society. Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Mov Disord 2018; 33 (01) 75-87
    CrossrefPubMedGoogle Scholar
  • 73 Louis ED, McCreary M. How common is essential tremor? Update on the worldwide prevalence of essential tremor. Tremor Other Hyperkinet Mov (N Y) 2021; 11: 28
    CrossrefPubMedGoogle Scholar
  • 74 Louis ED, Ottman R. How many people in the USA have essential tremor? Deriving a population estimate based on epidemiological data. Tremor Other Hyperkinet Mov (N Y) 2014; 4: 259
    CrossrefPubMedGoogle Scholar
  • 75 Marras C, Armstrong MJ, Meaney CA. et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013; 28 (05) 626-633
    CrossrefPubMedGoogle Scholar
  • 76 Benito-León J, Louis ED. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol 2006; 2 (12) 666-678 , quiz 2p, 691
    CrossrefPubMedGoogle Scholar
  • 77 Putzke JD, Whaley NR, Baba Y, Wszolek ZK, Uitti RJ. Essential tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg Psychiatry 2006; 77 (11) 1235-1237
    CrossrefPubMedGoogle Scholar
  • 78 Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 2010; 25 (05) 534-541
    CrossrefPubMedGoogle Scholar
  • 79 Dotchin CL, Walker RW. The prevalence of essential tremor in rural northern Tanzania. J Neurol Neurosurg Psychiatry 2008; 79 (10) 1107-1109
    CrossrefPubMedGoogle Scholar
  • 80 Okubadejo NU, Bankole IA, Ojo OO, Ojini FI, Danesi MA. Prevalence of essential tremor in urban Lagos, Nigeria: a door-to-door community-based study. BMC Neurol 2012; 12 (01) 110
    CrossrefPubMedGoogle Scholar
  • 81 Rautakorpi I, Takala J, Marttila RJ, Sievers K, Rinne UK. Essential tremor in a Finnish population. Acta Neurol Scand 1982; 66 (01) 58-67
    CrossrefPubMedGoogle Scholar
  • 82 Benito-León J, Bermejo-Pareja F, Morales JM, Vega S, Molina JA. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 2003; 18 (04) 389-394
    CrossrefPubMedGoogle Scholar
  • 83 Louis ED, Dogu O. Does age of onset in essential tremor have a bimodal distribution? Data from a tertiary referral setting and a population-based study. Neuroepidemiology 2007; 29 (3–4): 208-212
    CrossrefPubMedGoogle Scholar
  • 84 Louis ED, Huey ED, Cosentino S. Features of “ET plus” correlate with age and tremor duration: “ET plus” may be a disease stage rather than a subtype of essential tremor. Parkinsonism Relat Disord 2021; 91: 42-47
    CrossrefPubMedGoogle Scholar
  • 85 Iglesias-Hernandez D, Delgado N, McGurn M, Huey ED, Cosentino S, Louis ED. “ET Plus”: instability of the diagnosis during prospective longitudinal follow-up of essential tremor cases. Front Neurol 2021; 12: 782694
    CrossrefPubMedGoogle Scholar
  • 86 Berry DS, Hernandez N, Clark LN, Louis ED. Lack of familial aggregation of the “Essential Tremor-Plus” phenotype in familial essential tremor. Neuroepidemiology 2022; 56 (05) 373-379
    CrossrefPubMedGoogle Scholar
  • 87 Grütz K, Klein C. Dystonia updates: definition, nomenclature, clinical classification, and etiology. J Neural Transm (Vienna) 2021; 128 (04) 395-404
    CrossrefPubMedGoogle Scholar
  • 88 Pana A, Saggu B. Dystonia. [Updated 2022 Sep 5]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022
    Google Scholar
  • 89 Ebiol B, Yalcin G, Dressler E, Altenmuller E, Krauss J. Epidemiology of Dystonia, in Treatment of Dystonia. Cambridge: Cambridge University Press; 2018
    Google Scholar
  • 90 Albanese A, Bhatia K, Bressman SB. et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28 (07) 863-873
    CrossrefPubMedGoogle Scholar
  • 91 Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol 2004; 3 (11) 673-678
    CrossrefPubMedGoogle Scholar
  • 92 Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012; 27 (14) 1789-1796
    CrossrefPubMedGoogle Scholar
  • 93 Medina A, Nilles C, Martino D, Pelletier C, Pringsheim T. The prevalence of idiopathic or inherited isolated dystonia: a systematic review and meta-analysis. Mov Disord Clin Pract (Hoboken) 2022; 9 (07) 860-868
    CrossrefPubMedGoogle Scholar
  • 94 Das SK, Banerjee TK, Biswas A. et al. Community survey of primary dystonia in the city of Kolkata, India. Mov Disord 2007; 22 (14) 2031-2036
    CrossrefPubMedGoogle Scholar
  • 95 Joensen P. High prevalence of primary focal dystonia in the Faroe Islands. Acta Neurol Scand 2016; 133 (01) 55-60
    CrossrefPubMedGoogle Scholar
  • 96 Saunders-Pullman R, Fuchs T, San Luciano M. et al. Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites. Mov Disord 2014; 29 (06) 812-818
    CrossrefPubMedGoogle Scholar
  • 97 UK10K Consortium, Deciphering Developmental Disorders Study, NIHR BioResource Rare Diseases Consortium. et al. Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia. Nat Genet 2017; 49 (02) 223-237
    CrossrefPubMedGoogle Scholar
  • 98 Zech M, Jech R, Boesch S. et al. Monogenic variants in dystonia: an exome-wide sequencing study. Lancet Neurol 2020; 19 (11) 908-918
    CrossrefPubMedGoogle Scholar
  • 99 Zech M, Boesch S, Maier EM. et al. Haploinsufficiency of KMT2B, encoding the lysine-specific histone methyltransferase 2B, results in early-onset generalized dystonia. Am J Hum Genet 2016; 99 (06) 1377-1387
    CrossrefPubMedGoogle Scholar
  • 100 Gorman KM, Meyer E, Kurian MA. Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B. Eur J Paediatr Neurol 2018; 22 (02) 245-256
    CrossrefPubMedGoogle Scholar
  • 101 Lange LM, Junker J, Loens S. et al. Genotype-phenotype relations for isolated dystonia genes: MDSGene systematic review. Mov Disord 2021; 36 (05) 1086-1103
    CrossrefPubMedGoogle Scholar
  • 102 Gilmour GS, Lidstone SC, Lang AE. The diagnosis of functional movement disorder. Pract Neurol 2022; (March/April): 40-53
    PubMedGoogle Scholar
  • 103 Bennett K, Diamond C, Hoeritzauer I. et al. A practical review of functional neurological disorder (FND) for the general physician. Clin Med (Lond) 2021; 21 (01) 28-36
    CrossrefPubMedGoogle Scholar
  • 104 Carson A, Hallett M, Stone J. Assessment of patients with functional neurologic disorders. Handb Clin Neurol 2016; 139: 169-188
    CrossrefPubMedGoogle Scholar
  • 105 Stone J, Carson A, Duncan R. et al. Who is referred to neurology clinics?–the diagnoses made in 3781 new patients. Clin Neurol Neurosurg 2010; 112 (09) 747-751
    CrossrefPubMedGoogle Scholar
  • 106 Carson AJ, Brown R, David AS. et al; UK-FNS. Functional (conversion) neurological symptoms: research since the millennium. J Neurol Neurosurg Psychiatry 2012; 83 (08) 842-850
    CrossrefPubMedGoogle Scholar
  • 107 Espay AJ, Aybek S, Carson A. et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 2018; 75 (09) 1132-1141
    CrossrefPubMedGoogle Scholar
  • 108 Bodde NM, Brooks JL, Baker GA, Boon PA, Hendriksen JG, Aldenkamp AP. Psychogenic non-epileptic seizures–diagnostic issues: a critical review. Clin Neurol Neurosurg 2009; 111 (01) 1-9
    CrossrefPubMedGoogle Scholar
  • 109 MacDuffie KE, Grubbs L, Best T. et al. Stigma and functional neurological disorder: a research agenda targeting the clinical encounter. CNS Spectr 2020; 3: 1-6
    PubMedGoogle Scholar
  • 110 Lidstone SC, Costa-Parke M, Robinson EJ, Ercoli T, Stone J. FMD GAP Study Group. Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases. J Neurol Neurosurg Psychiatry 2022; 93 (06) 609-616
    CrossrefPubMedGoogle Scholar
  • 111 Deka K, Chaudhury PK, Bora K, Kalita P. A study of clinical correlates and socio-demographic profile in conversion disorder. Indian J Psychiatry 2007; 49 (03) 205-207
    CrossrefPubMedGoogle Scholar
  • 112 Naidoo L, Bhigjee AI. The spectrum of functional neurological disorders: a retrospective analysis at a tertiary hospital in South Africa. S Afr J Psychiatr 2021; 27: 1607
    PubMedGoogle Scholar
  • 113 Aybek S, Lidstone SC, Nielsen G. et al. What is the role of a specialist assessment clinic for FND? Lessons from three national referral centers. J Neuropsychiatry Clin Neurosci 2020; 32 (01) 79-84
    CrossrefPubMedGoogle Scholar
  • 114 Stephen CD, Fung V, Lungu CI, Espay AJ. Assessment of emergency department and inpatient use and costs in adult and pediatric functional neurological disorders. JAMA Neurol 2021; 78 (01) 88-101
    CrossrefPubMedGoogle Scholar
  • 115 Ueda K, Black KJ. A comprehensive review of tic disorders in children. J Clin Med 2021; 10 (11) 24479
    CrossrefPubMedGoogle Scholar
  • 116 Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol 2012; 47 (02) 77-90
    CrossrefPubMedGoogle Scholar
  • 117 Robakis D. How much do we know about adult-onset primary tics? prevalence, epidemiology, and clinical features. Tremor Other Hyperkinet Mov (N Y) 2017; 7: 441
    CrossrefPubMedGoogle Scholar
  • 118 Levine JLS, Szejko N, Bloch MH. Meta-analysis: adulthood prevalence of Tourette syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2019; 95: 109675
    CrossrefPubMedGoogle Scholar
  • 119 Kumar A, Trescher W, Byler D. Tourette syndrome and comorbid neuropsychiatric conditions. Curr Dev Disord Rep 2016; 3 (04) 217-221
    CrossrefPubMedGoogle Scholar
  • 120 Jones K, Saylam E, Ramphul K. Tourette Syndrome And Other Tic Disorders. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022
    Google Scholar
  • 121 Snider LA, Seligman LD, Ketchen BR. et al. Tics and problem behaviors in schoolchildren: prevalence, characterization, and associations. Pediatrics 2002; 110 (2, Pt 1): 331-336
    CrossrefPubMedGoogle Scholar
  • 122 Cox JH, Nahar A, Termine C. et al. Social stigma and self-perception in adolescents with tourette syndrome. Adolesc Health Med Ther 2019; 10: 75-82
    PubMedGoogle Scholar
  • 123 Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol 2007; 7 (06) 360-373
    CrossrefPubMedGoogle Scholar
  • 124 Bovenzi R, Conti M, Cerroni R. et al. Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. Neurol Sci 2022; 43 (01) 387-392
    CrossrefPubMedGoogle Scholar
  • 125 McColgan P, Tabrizi SJ. Huntington's disease: a clinical review. Eur J Neurol 2018; 25 (01) 24-34
    CrossrefPubMedGoogle Scholar
  • 126 Medina A, Mahjoub Y, Shaver L, Pringsheim T. Prevalence and incidence of Huntington's disease: an updated systematic review and meta-analysis. Mov Disord 2022; 37 (12) 2327-2335
    CrossrefPubMedGoogle Scholar
  • 127 Squitieri F, Andrew SE, Goldberg YP. et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 1994; 3 (12) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 128 Warby SC, Montpetit A, Hayden AR. et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009; 84 (03) 351-366
    CrossrefPubMedGoogle Scholar
  • 129 Hayden MR, MacGregor JM, Beighton PH. The prevalence of Huntington's chorea in South Africa. S Afr Med J 1980; 58 (05) 193-196
    PubMedGoogle Scholar
  • 130 Baine FK, Kay C, Ketelaar ME. et al. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. Eur J Hum Genet 2013; 21 (10) 1120-1127
    CrossrefPubMedGoogle Scholar
  • 131 Badry R, Abdelhamed MA, Sayed MAM, ElHady AA, Mostafa M. Epidemiology of dystonia, chorea, and athetosis in Al Quseir City (Red Sea Governorate), Egypt. Egypt J Neurol Psychiat Neurosurg 2019; 55 (01) 58
    CrossrefPubMedGoogle Scholar
  • 132 al Rajeh S, Bademosi O, Ismail H. et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology 1993; 12 (03) 164-178
    CrossrefPubMedGoogle Scholar
  • 133 Demiroren K, Yavuz H, Cam L, Oran B, Karaaslan S, Demiroren S. Sydenham's chorea: a clinical follow-up of 65 patients. J Child Neurol 2007; 22 (05) 550-554
    CrossrefPubMedGoogle Scholar
  • 134 Ben Hamida M, Hamza F. Sydenham's chorea in Tunisia: a report on 65 cases (author's transl) [in French]. Ann Med Interne (Paris) 1979; 130 (6–7): 359-364
    PubMedGoogle Scholar
  • 135 Tumas V, Caldas CT, Santos AC, Nobre A, Fernandes RMF. Sydenham's chorea: clinical observations from a Brazilian movement disorder clinic. Parkinsonism Relat Disord 2007; 13 (05) 276-283
    CrossrefPubMedGoogle Scholar
  • 136 Wenning GK, Geser F, Krismer F. et al; European Multiple System Atrophy Study Group. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12 (03) 264-274
    CrossrefPubMedGoogle Scholar
  • 137 Yabe I, Soma H, Takei A, Fujiki N, Yanagihara T, Sasaki H. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci 2006; 249 (02) 115-121
    CrossrefPubMedGoogle Scholar
  • 138 Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 2014; 42 (03) 174-183
    CrossrefPubMedGoogle Scholar
  • 139 van de Warrenburg BPC, Sinke RJ, Verschuuren-Bemelmans CC. et al. Spinocerebellar ataxias in the Netherlands: prevalence and age at onset variance analysis. Neurology 2002; 58 (05) 702-708
    CrossrefPubMedGoogle Scholar
  • 140 Hersheson J, Haworth A, Houlden H. The inherited ataxias: genetic heterogeneity, mutation databases, and future directions in research and clinical diagnostics. Hum Mutat 2012; 33 (09) 1324-1332
    CrossrefPubMedGoogle Scholar
  • 141 Jacquemont ML, Sanlaville D, Redon R. et al. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. J Med Genet 2006; 43 (11) 843-849
    CrossrefPubMedGoogle Scholar
  • 142 Brussino A, Gellera C, Saluto A. et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005; 64 (01) 145-147
    CrossrefPubMedGoogle Scholar
  • 143 Van Esch H, Bauters M, Ignatius J. et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 2005; 77 (03) 442-453
    CrossrefPubMedGoogle Scholar
  • 144 Macpherson J, Waghorn A, Hammans S, Jacobs P. Observation of an excess of fragile-X premutations in a population of males referred with spinocerebellar ataxia. Hum Genet 2003; 112 (5-6): 619-620
    CrossrefPubMedGoogle Scholar
  • 145 Polo JM, Calleja J, Combarros O, Berciano J. Hereditary ataxias and paraplegias in Cantabria, Spain. An epidemiological and clinical study. Brain 1991; 114 (Pt 2): 855-866
    CrossrefPubMedGoogle Scholar
  • 146 Kirilenko NB, Fedotov VP, Baryshnikova NV, Dadali EL, Poliakov AV. Nozological spectrum of hereditary diseases of the nervous system in the cities of Volgograd and Volzhsky [in Russian]. Genetika 2004; 40 (09) 1262-1267
    PubMedGoogle Scholar
  • 147 Vankan P. Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem 2013; 126 (Suppl. 01) 11-20
    CrossrefPubMedGoogle Scholar
  • 148 McCoy TH, Castro VM, Cagan A, Roberson AM, Kohane IS, Perlis RH. Sentiment measured in hospital discharge notes is associated with readmission and mortality risk: an electronic health record study. PLoS One 2015; 10 (08) e0136341
    CrossrefPubMedGoogle Scholar
  • 149 Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004; 3 (02) 93-103
    CrossrefPubMedGoogle Scholar
  • 150 Nath U, Ben-Shlomo Y, Thomson RG. et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain 2001; 124 (Pt 7): 1438-1449
    CrossrefPubMedGoogle Scholar
  • 151 Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011; 124 (03) 182-187
    CrossrefPubMedGoogle Scholar
  • 152 Vicente E, Ruiz de Sabando A, García F, Gastón I, Ardanaz E, Ramos-Arroyo MA. Validation of diagnostic codes and epidemiologic trends of Huntington disease: a population-based study in Navarre, Spain. Orphanet J Rare Dis 2021; 16 (01) 77
    CrossrefPubMedGoogle Scholar
  • 153 Kim HS, Lyoo CH, Lee PH. et al. Current status of Huntington's disease in Korea: a nationwide survey and national registry analysis. J Mov Disord 2015; 8 (01) 14-20
    CrossrefPubMedGoogle Scholar
  • 154 Adachi Y, Nakashima K. Population genetic study of Huntington's disease–prevalence and founder's effect in the San-in area, western Japan [in Japanese]. Jpn J Clin Med 1999; 57 (04) 900-904
    PubMedGoogle Scholar
  • 155 Chen YY, Lai CH. Nationwide population-based epidemiologic study of Huntington's Disease in Taiwan. Neuroepidemiology 2010; 35 (04) 250-254
    CrossrefPubMedGoogle Scholar
  • 156 Scrimgeour EM. Huntington disease (chorea) in the middle East. Sultan Qaboos Univ Med J 2009; 9 (01) 16-23
    PubMedGoogle Scholar
  • 157 Cubo E, Doumbe J, Mapoure Njankouo Y. et al. The burden of movement disorders in Cameroon: a rural and urban-based inpatient/outpatient study. Mov Disord Clin Pract (Hoboken) 2017; 4 (04) 568-573
    CrossrefPubMedGoogle Scholar
  • 158 Peterlin B, Kobal J, Teran N, Flisar D, Lovrecić L. Epidemiology of Huntington's disease in Slovenia. Acta Neurol Scand 2009; 119 (06) 371-375
    CrossrefPubMedGoogle Scholar
  • 159 Muroni A, Murru MR, Sechi M. et al. Prevalence of Huntington's disease in Southern Sardinia, Italy. Parkinsonism Relat Disord 2020; 80: 54-57
    CrossrefPubMedGoogle Scholar
  • 160 Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry 2013; 84 (10) 1156-1160
    CrossrefPubMedGoogle Scholar
  • 161 Gilling M, Budtz-Jørgensen E, Boonen SE. et al. The Danish HD Registry-a nationwide family registry of HD families in Denmark. Clin Genet 2017; 92 (03) 338-341
    CrossrefPubMedGoogle Scholar
  • 162 Ohlmeier C, Saum KU, Galetzka W, Beier D, Gothe H. Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data. BMC Neurol 2019; 19 (01) 318
    CrossrefPubMedGoogle Scholar
  • 163 Exuzides A, Reddy SR, Chang E. et al. Epidemiology of Huntington's disease in the United States Medicare and Medicaid populations. Neuroepidemiology 2022; 56 (03) 192-200
    CrossrefPubMedGoogle Scholar
  • 164 Scahill L, Specht M, Page C. The prevalence of tic disorders and clinical characteristics in children. J Obsessive Compuls Relat Disord 2014; 3 (04) 294-400
    PubMedGoogle Scholar